About 4.5 million adults in the United States have psoriasis,1 a chronic, often uncomfortable and disfiguring disease typically lasting more than 30 years. Approximately half a million individuals find the disease a substantial problem in everyday life. Fewer than half of those affected by psoriasis find their treatment highly satisfactory.1
Although available treatment options for patients with severe psoriasis have changed little over nearly 20 years, psoriasis has recently become a focus for innovative therapies. With the development of monoclonal antibodies that alter immune function, 4 new products—2 antibodies that modulate T-cell functions (efalizumab and alefacept) and 2 tumor necrosis factor α inhibitors (infliximab and etanercept)—have demonstrated beneficial effects on moderate to severe psoriasis. In this issue of THE JOURNAL, Gordon et al2 report on the effect of efalizumab on psoriasis as measured by both physician and patient assessment. This and other studies demonstrate that efalizumab is superior to placebo.2- 4 To determine the place of efalizumab in the current therapeutic armamentarium, however, its safety and efficacy must be determined relative to other therapies for severe psoriasis.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 22
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Register Now
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Need assistance?
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.